Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Michelle Shayne, R. Donald Harvey & Gary H. Lyman. (2021) Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity. Expert Review of Anticancer Therapy 21:10, pages 1145-1159.
Read now
Read now
Derek Weycker, Mark Bensink, Alexander Lonshteyn, Robin Doroff & David Chandler. (2019) Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment. Current Medical Research and Opinion 35:6, pages 1073-1080.
Read now
Read now
Derek Weycker, Ahuva Hanau, Alexander Lonshteyn, Charles Bowers, Mark Bensink, Tamer Garawin & David Chandler. (2018) Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged ≥65 years: a retrospective evaluation using Medicare claims. Current Medical Research and Opinion 34:9, pages 1705-1711.
Read now
Read now
Mark Bensink, Christine Edwards, Charles Bowers & Jon Campbell. (2018) Response to: McBride A, Campbell K, Bikkina M, et al. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. J Med Econ 2017;20:1083–93. Journal of Medical Economics 21:6, pages 603-605.
Read now
Read now
Articles from other publishers (17)
Marc Rehlinghaus, Philipp Rehker, Yue Che, Camilla Marisa Grunewald & Günter Niegisch. (2023) Neutropenie – wann ist eine GCSF Unterstützung notwendig?. Aktuelle Urologie.
Crossref
Crossref
Shu-Wei Hsu, Shao-Chin Chiang, Jason C. Hsu & Yu Ko. (2023) Prescription patterns of granulocyte colony–stimulating factors in patients with breast cancer: A real-world study. PLOS ONE 18:7, pages e0288642.
Crossref
Crossref
Sophia Z. Humphreys, Robert B. Geller & Paul Walden. (2022) Pegfilgrastim Biosimilars in US Supportive Oncology: A Narrative Review of Administration Options and Economic Considerations to Maximize Patient Benefit. Oncology and Therapy 10:2, pages 351-361.
Crossref
Crossref
Douglas W. Blayney & Lee Schwartzberg. (2022) Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review. Cancer Treatment Reviews 109, pages 102427.
Crossref
Crossref
Neda Alrawashdh, Jamie Vraney, Briana M Choi, Abdulaali R Almutairi, Ivo Abraham & Ali McBride. (2022) Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer. Future Oncology 18:19, pages 2381-2390.
Crossref
Crossref
Mark D. Danese, Jennifer Schenfeld, Jaime Shaw, Prasad Gawade, Akhila Balasubramanian, Michael Kelsh, Rohini K. Hernandez & Gary Lyman. (2022) Association Between Granulocyte Colony-Stimulating Factor (G-CSF) Use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly Patients with Breast, Lung, or Prostate Cancer. Advances in Therapy 39:6, pages 2778-2795.
Crossref
Crossref
Wei Tian, Yali Wang, Yunxiang Zhou, Yihan Yao & Yongchuan Deng. (2022) Effects of Prophylactic Administration of Granulocyte Colony-Stimulating Factor on Peripheral Leukocyte and Neutrophil Counts Levels After Chemotherapy in Patients With Early-Stage Breast Cancer: A Retrospective Cohort Study. Frontiers in Oncology 12.
Crossref
Crossref
Reshma Mahtani, Jeffrey Crawford, Sinéad M. Flannery, Tatiana Lawrence, Jennifer Schenfeld & Prasad L. Gawade. (2021) Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety. BMC Cancer 21:1.
Crossref
Crossref
Ali McBride, Neda Alrawashdh, Trace Bartels, Logan Moore, Daniel Persky & Ivo Abraham. (2021) Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy. Future Oncology 17:26, pages 3485-3497.
Crossref
Crossref
Xiaohua Ma, Jian Kang, Yufang Li & Xiaojian Zhang. (2021) Pegfilgrastim safety and efficacy on the last chemotherapy day versus the next: systematic review and meta-analysis. BMJ Supportive & Palliative Care, pages bmjspcare-2020-002532.
Crossref
Crossref
Jeffrey Crawford, Donald C. Moore, Vicki A. Morrison & David Dale. (2021) Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage. Cancer Treatment and Research Communications 29, pages 100466.
Crossref
Crossref
Amanda J Gerberich, Mark R Attilio & Alison Svoboda. (2020) Revisiting same day administration of pegfilgrastim in the age of biosimilars: A review of literature. Journal of Oncology Pharmacy Practice 26:8, pages 1970-1976.
Crossref
Crossref
Prasad L. Gawade, Shuling Li, David Henry, Nancy Smith, Rajesh Belani, Michael A. Kelsh & Brian D. Bradbury. (2020) Patterns of granulocyte colony–stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. Supportive Care in Cancer 28:9, pages 4413-4424.
Crossref
Crossref
Derek Weycker, Robin Doroff, Ahuva Hanau, Charles Bowers, Rajesh Belani, David Chandler, Alexander Lonshteyn, Mark Bensink & Gary H. Lyman. (2019) Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study. BMC Cancer 19:1.
Crossref
Crossref
Derek Weycker, Mark Hatfield, Aaron Grossman, Ahuva Hanau, Alex Lonshteyn, Anjali Sharma & David Chandler. (2019) Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer 19:1.
Crossref
Crossref
David H. Henry, Derek Weycker, Mark Bensink, Prasad Gawade & Rajesh Belani. (2019) Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies: response to study by Hayama et al.. International Journal of Clinical Pharmacy 41:3, pages 619-620.
Crossref
Crossref
Tatsuya Hayama, Kenichi Sakurai, Katsuhiro Miura, Shinsaku Washinosu, Shinya Tsuboi, Akihiro Uchiike, Yoshikazu Yoshida & Masami Takei. (2018) Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies. International Journal of Clinical Pharmacy 40:5, pages 997-1000.
Crossref
Crossref